New drug shows promise for rare muscle disease in early trial
NCT ID NCT04004000
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tested a drug called losmapimod in 14 adults with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a rare genetic condition that causes muscle weakness. The main goal was to check if the drug is safe and tolerable, and to see how it affects certain markers in the blood and muscles. The trial was stopped early, but the results help researchers understand if losmapimod might control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Radboud University Medical Center
Nijmegen, 9101, Netherlands
Conditions
Explore the condition pages connected to this study.